Former Chief Financial Officer, former principal financial officer, and former principal executive officer · Avalo Therapeutics, Inc. (AVTX)

Joseph Miller

A named executive officer of Avalo Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$232,269

Salary $116,748Stock awards $0

FY2019: $1,170,598

4th of 4 named executive officers at Avalo Therapeutics by FY2020 total.

4 named officers on file for Avalo Therapeutics, FY2020

Joseph Miller’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Avalo Therapeutics’s whole pay program stands against its peers

  • Avalo Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2021 (DEF 14A).

Free

Get Joseph Miller’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Joseph Miller compensation by year

Avalo Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Avalo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$153,600$356,000$116,748
Bonus$61,370$222,000$0
Stock awards$202,500$0$0
Option awards$255,515$592,598$0
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$0$0$115,521
Total$672,985$1,170,598$232,269

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Avalo Therapeutics, Inc. DEF 14A filed April 27, 2021, accession 0001628280-21-007742, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Avalo Therapeutics, Inc. filed document, accession 0001628280-21-007742. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2021.

$673K
$1.2M
$232K
FY18
FY19
FY20
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option25,000—$2.51
Option41,563—$4.50
Option102,083—$6.22
RSU22,500——

Per the Outstanding Equity Awards at Fiscal Year-End table in Avalo Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Avalo Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Michael ColaFormer Chief Executive Officer and former principal executive officer$3,820,306
Garry NeilChief Scientific Officer$2,688,804
H. Jeffrey WilkinsFormer Chief Medical Officer$1,487,778
Joseph Miller · this pageFormer Chief Financial Officer, former principal financial officer, and former principal executive officer$232,269

Board service

Avalo Therapeutics board · FY2021–FY2022
Director compensation in US dollars, as Avalo Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2022$8,242—$10,000$0$18,242
FY2021$0—$138,421$0$138,421

Each year as the company reported it in Avalo Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Avalo Therapeutics pays directors a $40,000 cash retainer and $20,100 in Options. As stated in Avalo Therapeutics's FY2025 proxy.

The full Avalo Therapeutics compensation record

free company brief

This page is one person within Avalo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Avalo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Miller's compensation dossier · One-time report. No refunds.